Lv33
280 积分 2024-12-16 加入
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas
1天前
已完结
Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas
1天前
已关闭
Primary Large B-cell Lymphomas of Immune-Privileged Sites
5个月前
已完结
Intravenous esomeprazole pharmacodynamics in critically ill patients
5个月前
已关闭
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
5个月前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
9个月前
已完结
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models
9个月前
已完结
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
9个月前
已完结
New bispecific antibodies in diffuse large B-cell lymphoma
9个月前
已完结
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
11个月前
已完结
皖公网安备34019202002308
